Quantum BioPharma is trading 5.5% down at $3.09, with biotech-sector weakness a possible contributing factor.
- On October 6, the company announced a Thermo Fisher agreement to support start-up of its Phase 2 Lucid-MS trial; the development does not directly explain the decline.
- XBI is down 2.50% during the regular session, while broad U.S. indexes are higher. No trading-volume details were available, so the precise cause remains unclear.